SCHEMBL19636516

SCHEMBL19636516

Nc1nc(O)c2ncc([C@@H]3O[C@H](CO)C(O)C3(Cl)Cl)n2n1

nearest known ligand 0.32

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ADORA2A P29274 1/20 0.32
▸ PDE4D Q08499 1/20 0.31
▸ PDE3A Q14432 1/20 0.31
▸ SLC29A1 Q99808 1/20 0.31
▸ GMNN O75496 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ NFKB1 P19838 1/20 0.30
▸ DNMT1 P26358 1/20 0.30
▸ THPO P40225 1/20 0.30
▸ MTOR P42345 1/20 0.30
▸ HTT P42858 1/20 0.30
▸ RAB9A P51151 1/20 0.30
▸ BLM P54132 1/20 0.30
▸ HBB P68871 1/20 0.30
▸ PMP22 Q01453 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19632890 1.00 ADORA2A (0.32) ADORA2APDE4DPDE3ASLC29A1GMNN
SCHEMBL18480783 0.90 PDE4D (0.34) ADORA2APDE4DPDE3ASLC29A1
SCHEMBL18470929 0.90 PDE4D (0.34) ADORA2APDE4DPDE3ASLC29A1
SCHEMBL19636519 0.90 ADORA2A (0.34) ADORA2APDE4DPDE3ASLC29A1GMNN
SCHEMBL19632929 0.90 ADORA2A (0.34) ADORA2APDE4DPDE3ASLC29A1GMNN
SCHEMBL19632941 0.87 SLC29A1 (0.31) ADORA2APDE4DPDE3ASLC29A1GMNN
SCHEMBL19636530 0.87 SLC29A1 (0.31) ADORA2APDE4DPDE3ASLC29A1GMNN
SCHEMBL19229291 0.85 PDE4D (0.34) PDE4DPDE3ASLC29A1
SCHEMBL19229337 0.85 PDE4D (0.34) PDE4DPDE3ASLC29A1
SCHEMBL19636515 0.84 PDE4D (0.32) PDE4DPDE3ASLC29A1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170334941-A1 2',2'-DIHALO NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER EMORY UNIVERSITY 2017-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170334941-A1 2',2'-DIHALO NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCER HAVCR2, DERA, EIF2AK2 ADORA2A 139/4885PDE4D 2437/4885PDE3A 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback